Tralokinumab (Adbry)

What is Tralokinumab?

Tralokinumab (Adbry) is an injectable biologic medication primarily used to treat moderate-to-severe atopic dermatitis (eczema) in patients whose disease is not adequately controlled with topical prescription treatments or when those treatments are not a good fit. It is one of the targeted biologic options now available for eczema and can be used with or without topical corticosteroids.

How does Tralokinumab work?

Tralokinumab works by targeting interleukin-13 (IL-13), an important inflammatory signal involved in eczema. By blocking IL-13, tralokinumab helps reduce skin inflammation, itch, and barrier dysfunction.

What are possible side effects of Tralokinumab?

Common side effects include upper respiratory symptoms, conjunctivitis, injection site reactions, and eosinophilia. Patients who develop new or worsening eye symptoms should contact their healthcare provider, since conjunctivitis and keratitis are specifically addressed in the prescribing information.

How is Tralokinumab used?

Tralokinumab is given by subcutaneous injection. Treatment begins with a loading phase followed by maintenance treatment, and the adult and adolescent loading schedules are not identical. Some patients may be able to self-inject after proper training, and it may be used alongside topical corticosteroids or selected nonsteroidal topicals for problem areas.

Before starting tralokinumab, your provider may review vaccination status and overall treatment history. Live vaccines are generally avoided during treatment.